Raymond James analyst Jonathan Hughes double downgraded Omega Healthcare to Market Perform from Strong Buy as it has surpassed the previous $44 price target and the risk/reward profile appears balanced. While his constructive view on Omega is unchanged, upside catalysts to drive shares above and beyond the current price seem unlikely in the near-term, Hughes tells investors in a research note. Omega is well-positioned to capitalize on the "Silver Tsunami" of aging demographics and generate strong earnings, NAV and dividend growth for shareholders, but Hughes believes a more prudent approach to the stock is now appropriate.